Medical weight loss is the fastest-growing category in aesthetics and the hardest to advertise. Every clinic wants to name the drug, the platform does not want them to, and the ones that work it out have a structural advantage over the ones still getting rejected.
Why naming the molecule fails
Prescription medication in ad copy is restricted on Meta, and enforcement on GLP-1-class drugs has been both aggressive and inconsistent — which is worse than aggressive alone, because it means a campaign that ran for three weeks can stop without warning.
Stack on top of that Meta's Personal Attributes policy, which prohibits ads asserting or implying knowledge of the viewer's health, and the health and wellness rules restricting before/after imagery and any framing that generates negative self-perception.
The result is that the three things a weight loss clinic instinctively wants to do — name the drug, show the transformation, speak to the struggle — are all prohibited.
Sell the supervision, not the substance. It is the compliant answer and the better one.
What to advertise instead
The program. "Medically supervised weight loss" describes what you actually sell. The drug is a commodity available from a dozen telehealth companies at a lower price; the supervision, the labs, the dose titration and the person who answers when something feels wrong are not.
The candidacy question. "A consultation to find out whether you're a candidate" is compliant, honest, and converts well, because it is a smaller commitment than "start today" and it is what actually happens next.
The monitoring. Bloodwork, follow-up cadence, the physician who reviews it. This is the genuine differentiator against telehealth, and it is the thing patients who have had a bad experience elsewhere are looking for.
The person. A clinician on camera explaining how the program works outperforms almost anything else we have run in this category — and it sits comfortably inside the rules, because it is about the practice rather than the viewer.
Copy that gets approved
| Rejected | Approved |
|---|---|
| "Struggling to lose weight?" | "Medically supervised weight loss in Tampa" |
| "Lose 20lbs with [drug name]" | "A physician-monitored program with labs and follow-up" |
| "Finally get your body back" | "See whether you're a candidate — 15-minute consultation" |
| Before/after split image | A clinician explaining the monitoring |
The compounded question
Compounded GLP-1s are a separate and more serious issue than an ad rejection. Regulatory attention to compounded semaglutide has been significant and the landscape has shifted repeatedly. Advertising claims about compounded products carry exposure well beyond Meta's policies — FDA, state boards, and state consumer protection law all have a view.
We do not write ad copy making efficacy or equivalence claims about compounded medications. If a client sells them, the advertising sells the consultation and the clinical conversation happens in the room with someone licensed to have it.
The economics are unusually good
Weight loss is a monthly relationship, not a transaction. A patient on a protocol has a twelve-month value that dwarfs a single aesthetic treatment, which means you can pay far more per lead than a med spa selling a one-off and still be buying patients at a discount.
That is the reason this category is worth the advertising difficulty. Run the arithmetic properly — what a new patient should actually cost your clinic — before deciding what you can afford, because the intuitive answer is usually far too low.
If your weight loss ads are stuck in a rejection loop, the fix is almost always in the copy rather than the account, and it takes about an hour.